These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8930427)

  • 1. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube.
    Chun AH; Shi HH; Achari R; Dennis S; Cavanaugh JH
    Clin Ther; 1996; 18(5):833-42. PubMed ID: 8930427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lansoprazole: an alternative method of administration of a capsule dosage formulation.
    Chun AH; Eason CJ; Shi HH; Cavanaugh JH
    Clin Ther; 1995; 17(3):441-7. PubMed ID: 7585848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of lansoprazole granules administered in juice or soft food compared with the intact capsule formulation.
    Chun AH; Erdman K; Chiu YL; Pilmer BL; Achari R; Cavanaugh JH
    Clin Ther; 2002 Aug; 24(8):1322-31. PubMed ID: 12240782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect on bioavailability of admixing the contents of lansoprazole capsules with selected soft foods.
    Chun AH; Erdman K; Zhang Y; Achari R; Cavanaugh JH
    Clin Ther; 2000 Feb; 22(2):231-6. PubMed ID: 10743982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects.
    Doan TT; Wang Q; Griffin JS; Lukasik NL; O'Dea RF; Pan WJ
    Am J Health Syst Pharm; 2001 Aug; 58(16):1512-9. PubMed ID: 11515348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules.
    Amer F; Karol MD; Pan WJ; Griffin JS; Lukasik NL; Locke CS; Chiu YL
    Clin Ther; 2004 Dec; 26(12):2076-83. PubMed ID: 15823771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects.
    Freston JW; Chiu YL; Mulford DJ; Ballard ED
    Aliment Pharmacol Ther; 2003 Feb; 17(3):361-7. PubMed ID: 12562448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
    Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
    Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and absolute bioavailability of lansoprazole.
    Gerloff J; Mignot A; Barth H; Heintze K
    Eur J Clin Pharmacol; 1996; 50(4):293-7. PubMed ID: 8803522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants.
    Undre N; Dickinson J
    BMJ Open; 2017 Apr; 7(4):e012252. PubMed ID: 28377389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube.
    Freston JW; Kukulka MJ; Lloyd E; Lee C
    Aliment Pharmacol Ther; 2004 Aug; 20(4):407-11. PubMed ID: 15298634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability and efficacy of omeprazole given orally and by nasogastric tube.
    Larson C; Cavuto NJ; Flockhart DA; Weinberg RB
    Dig Dis Sci; 1996 Mar; 41(3):475-9. PubMed ID: 8617118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate.
    Sharma VK; Peyton B; Spears T; Raufman JP; Howden CW
    Aliment Pharmacol Ther; 2000 Jul; 14(7):887-92. PubMed ID: 10886044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study.
    Islam MS; Trini AB; Shohag H; Ahmed MU; Maruf AA; Hasnat A
    Int J Clin Pharmacol Ther; 2011 Dec; 49(12):778-86. PubMed ID: 22122821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube.
    Podilsky G; Berger-Gryllaki M; Testa B; Buclin T; Roulet M; Pannatier A
    Eur J Clin Pharmacol; 2009 May; 65(5):435-42. PubMed ID: 19189088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe.
    Gremse DA; Donnelly JR; Kukulka MJ; Lloyd E; Lee C
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1211-5. PubMed ID: 15153174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.
    Portolés A; Calvo A; Terleira A; Laredo L; Resplandy G; Gorostiaga C; Moreno A
    J Clin Pharmacol; 2006 Oct; 46(10):1195-203. PubMed ID: 16988209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of oral doses of lansoprazole and omeprazole on gastric pH.
    Tolman KG; Sanders SW; Buchi KN; Karol MD; Jennings DE; Ringham GL
    J Clin Gastroenterol; 1997 Mar; 24(2):65-70. PubMed ID: 9077718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of omeprazole and lansoprazole granules through a nasogastric tube in vitro.
    Dunn A; White CM; Reddy P; Quercia RA; Chow MS
    Am J Health Syst Pharm; 1999 Nov; 56(22):2327-30. PubMed ID: 10582827
    [No Abstract]   [Full Text] [Related]  

  • 20. Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.
    Niioka T; Yasui-Furukori N; Uno T; Sugawara K; Kaneko S; Tateishi T
    Ther Drug Monit; 2006 Jun; 28(3):321-5. PubMed ID: 16778714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.